← brief for 2026-09-23 · Slowing decline

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria

Key takeaways

A new drug called lorundrostat was tested in people with kidney disease and high blood pressure. The drug lowered blood pressure and was safe. This is a Phase 2 trial, which is a smaller test before a final decision. It shows the drug works, but more testing is needed.

Source

Paper · Kidney International · 2026-09-23
https://www.kidney-international.org/article/S0085-2538(26)00808-2/fulltext?rss=yes